Back to search
FDAFDA · Food and drugs·Recall number D-0202-2019

Trimix Papaverine/Phentolamine/Alprostadil/Lidocaine 30 mg/1 mg/175 mcg/1 mg Powder Pharm D Solutions, Houston, Texas --- NDC 69699-1369-02

Published November 7, 2018 · Recall initiated: September 10, 2018

Summary

FDA records drug Class II recall D-0202-2019, published November 7, 2018 and initiated September 10, 2018. Recalling firm: Pharm D Solutions, LLC; Status: Terminated; Reported quantity: 195 vials; Lot: Lot: 05302018:59 Discard by: 11/26/2018; 06132018:44 Discard by: 12/10/2018; 06062018:64 Discard by: 12/3/2018; 07262018:97 Discard by: 11/1/2018; 07052018:23 Discard by: 1/1/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pharm D Solutions, LLC
Distributor
Nationwide
Lot
Lot: 05302018:59 Discard by: 11/26/2018; 06132018:44 Discard by: 12/10/2018; 06062018:64 Discard by: 12/3/2018; 07262018:97 Discard by: 11/1/2018; 07052018:23 Discard by: 1/1/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Trimix Papaverine/Phentolamine/Alprostadil/Lidocaine 30 mg/1 mg/175 mcg/1 mg Powder Pharm D Solutions, Houston, Texas --- NDC 69699-1369-02 recalled?

Yes. FDA published recall D-0202-2019 on November 7, 2018. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Press Release